Attachment XV - Page 15 
STANFORD UNIVERSITY MEDICAL CENTER 
STANFORD, CALIFORNIA 94305 
Dr. William J. Gartland 
Office of Recombinant DNA Activities 
National Institute of Allergy & Infeetious Diseases 
National Institutes of Health 
Bethesda, Maryland 20205 
Dear Dr. Gartland, 
I am writing to comment on the "Points to Consider in the Design 
and Submission of Human Somatic-Cell Gene Therapy Protocols" that was 
published in the Federal Register of January 22, 1985. 
I have read the questions that must be addressed by investigators 
planning genetic modifications of somatic cells for the treatment of 
certain human genetic diseases. They appear eminently reasonable, 
specific and thorough. I am certain that responding to the "points to 
be considered" will greatly aid the scientists and physicians to improve 
the quality of the protocols and outcomes of such contemplated ther- 
apies.. It will certainly help the Federal agencies charged with re- 
viewing and evaluating the merit of such proposed therapies. Moreover, 
the procedures outlined should also assure public confidence that such 
procedures are being undertaken with the utmost of care and supervision. 
DEPARTMENT OF BIOCHEMISTRY 
PAUL BERG 
Willson Professor of Biochemistry 
February 13, 1985 
Sincerely, 
PB/e 
[ 42 ] 
